A NEW phase 3 clinical trial has revealed that stem cells can help prevent heart failure in patients recovering from acute myocardial infarction. The study found that intracoronary infusion of mesenchymal stem cells significantly reduced the risk of heart failure and related complications.
Harnessing Stem Cells for Cardiac Repair
The therapeutic use of stem cells in cardiovascular medicine has long been investigated, but robust clinical evidence has remained limited. Heart failure is a major long-term complication after myocardial infarction, often leading to repeated hospital admissions and reduced quality of life. The PREVENT-TAHA8 study sought to determine whether intracoronary infusion of Wharton’s jelly derived mesenchymal stem cells could prevent the onset of heart failure in this high-risk population.
